Editorial
Venous Thromboembolic Disease and Cancer: A Challenge for Clinicians
Enfermedad tromboembólica venosa y cáncer: un reto para los clínicos
a Servicio de Neumología, Hospital Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
b Servicio de Neumología, Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Sevilla, Spain
Read
4597
Timeswas read the article
1673
Total PDF
2924
Total HTML
Share statistics
array:24 [ "pii" => "S1579212918301575" "issn" => "15792129" "doi" => "10.1016/j.arbr.2018.01.020" "estado" => "S300" "fechaPublicacion" => "2018-07-01" "aid" => "1815" "copyright" => "SEPAR" "copyrightAnyo" => "2018" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2018;54:359-60" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1344 "formatos" => array:3 [ "EPUB" => 114 "HTML" => 964 "PDF" => 266 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0300289618300231" "issn" => "03002896" "doi" => "10.1016/j.arbres.2018.01.008" "estado" => "S300" "fechaPublicacion" => "2018-07-01" "aid" => "1815" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2018;54:359-60" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3196 "formatos" => array:3 [ "EPUB" => 112 "HTML" => 2323 "PDF" => 761 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Enfermedad tromboembólica venosa y cáncer: un reto para los clínicos" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "359" "paginaFinal" => "360" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Venous Thromboembolic Disease and Cancer: A Challenge for Clinicians" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Deisy Barrios, Luis Jara-Palomares, David Jiménez" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Deisy" "apellidos" => "Barrios" ] 1 => array:2 [ "nombre" => "Luis" "apellidos" => "Jara-Palomares" ] 2 => array:2 [ "nombre" => "David" "apellidos" => "Jiménez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1579212918301575" "doi" => "10.1016/j.arbr.2018.01.020" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212918301575?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289618300231?idApp=UINPBA00003Z" "url" => "/03002896/0000005400000007/v1_201807020415/S0300289618300231/v1_201807020415/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1579212918301563" "issn" => "15792129" "doi" => "10.1016/j.arbr.2017.12.012" "estado" => "S300" "fechaPublicacion" => "2018-07-01" "aid" => "1807" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2018;54:361-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 739 "formatos" => array:3 [ "EPUB" => 111 "HTML" => 395 "PDF" => 233 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Augmentation Therapy Nowadays: Con" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "361" "paginaFinal" => "362" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Terapia de aumento en la actualidad: con" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juan Bautista Gáldiz Iturri" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Juan Bautista" "apellidos" => "Gáldiz Iturri" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0300289618300152" "doi" => "10.1016/j.arbres.2017.12.017" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289618300152?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212918301563?idApp=UINPBA00003Z" "url" => "/15792129/0000005400000007/v1_201807020412/S1579212918301563/v1_201807020412/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1579212918301447" "issn" => "15792129" "doi" => "10.1016/j.arbr.2018.05.002" "estado" => "S300" "fechaPublicacion" => "2018-07-01" "aid" => "1712" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2018;54:357-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1521 "formatos" => array:3 [ "EPUB" => 144 "HTML" => 962 "PDF" => 415 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "World Health Organization Positioning. The Impact of Tobacco in the Environment: Cultivation, Curing, Manufacturing, Transport, and Third and Fourth-hand Smoking" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "357" "paginaFinal" => "358" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Posicionamiento de la Organización Mundial de la Salud. Impacto del tabaco en el medio ambiente: cultivo, curado, manufactura, transporte y tabaquismo de tercera y cuarta mano" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José Ignacio de Granda-Orive, Carlos Andrés Jiménez-Ruiz, Segismundo Solano-Reina" "autores" => array:3 [ 0 => array:2 [ "nombre" => "José Ignacio" "apellidos" => "de Granda-Orive" ] 1 => array:2 [ "nombre" => "Carlos Andrés" "apellidos" => "Jiménez-Ruiz" ] 2 => array:2 [ "nombre" => "Segismundo" "apellidos" => "Solano-Reina" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0300289617302946" "doi" => "10.1016/j.arbres.2017.09.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289617302946?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212918301447?idApp=UINPBA00003Z" "url" => "/15792129/0000005400000007/v1_201807020412/S1579212918301447/v1_201807020412/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Venous Thromboembolic Disease and Cancer: A Challenge for Clinicians" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "359" "paginaFinal" => "360" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Deisy Barrios, Luis Jara-Palomares, David Jiménez" "autores" => array:3 [ 0 => array:3 [ "nombre" => "Deisy" "apellidos" => "Barrios" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "Luis" "apellidos" => "Jara-Palomares" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:4 [ "nombre" => "David" "apellidos" => "Jiménez" "email" => array:1 [ 0 => "djimenez.hrc@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Sevilla, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedad tromboembólica venosa y cáncer: un reto para los clínicos" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The risk of developing a venous thrombotic event is 4 times greater among cancer patients than the general population.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">1</span></a> In fact, around 20% of deep venous thrombosis and pulmonary embolisms are a result of an active cancer (i.e., cancer diagnosed in the previous year or in active treatment).<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">2</span></a> Venous thromboembolism (VTE) is the second cause of death among cancer patients.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">3</span></a> Moreover, cancer patients receiving anticoagulants due to VTE have a higher risk of recurrence and bleeding than anticoagulated patients without cancer.</p><p id="par0010" class="elsevierStylePara elsevierViewall">Pharmacological thromboprophylaxis is recommended in cancer patients who must be hospitalized due a medical condition, unless contraindicated. Similarly, patients with active cancer who are scheduled to undergo major surgery should receive pharmacological thromboprophylaxis. However, the evidence is much less consistent in cancer outpatients who are receiving chemotherapy. Scientific societies recommend the use of well-validated risk models, such as the Khorana model (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>) to identify subgroups of patients with a high risk of thrombotic events.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">4</span></a> Thromboprophylaxis with low molecular weight heparin (LMWH) should only be considered in patients with a score of ≥3 on the Khorana model or advanced pancreatic cancer, and patients with myeloma receiving thalidomide or lenalidomide may receive aspirin or LMWH.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">5</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">In patients with VTE and cancer, LMWH during the first 3–6 months is associated with a significantly lower risk of recurrent thrombosis than warfarin.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">6</span></a> It is still not completely clear whether patients should receive therapeutic doses of LMWH throughout their treatment, so we recommend using the LMWH regimen that has been tested in clinical trials for each product (i.e., full doses of enoxaparin and tinzaparin, and a 75% dose reduction for dalteparin after the first month). After this 3–6 month period of anticoagulation, the decision to continue anticoagulants depends on a number of factors, such as tumor activity, indication for anticancer treatment, patient's tolerance of anticoagulation, patient preferences, and cost and availability of treatment. No clinical trials have been published on the efficacy and safety of LMWH in cancer patients with VTE beyond the first 6 months of treatment. Chai-Adisaksopha et al. used data from the RIETE registry and propensity score matching to compare the efficacy and safety of vitamin K antagonists with LMWH in cancer patients with VTE after the first 6 months of treatment.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">7</span></a> Patients receiving LMWH had a similar rate of recurrent deep venous thrombosis (relative risk [RR] 1.41; 95% confidence interval [CI] 0.68–2.93), recurrent pulmonary thromboembolism (RR 0.73; 95% CI 0.34–1.58), major bleeding (RR 1.15; 95% CI 0.55–2.40), and non-major bleeding (RR 0.96; 95% CI 0.51–1.79) compared with those who received vitamin K antagonists, and a higher mortality rate (RR 1.58; 95% CI 1.13–2.20).</p><p id="par0020" class="elsevierStylePara elsevierViewall">Given the lack of consistent data to support their efficacy and safety in cancer patients, direct-acting anticoagulants (apixaban, dabigatran, edoxaban, and rivaroxaban) are not indicated in the treatment of VTE in these patients. However, data from the Hokusai VTE Cancer clinical trial<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">8</span></a> have recently been published, comparing edoxaban with dalteparin for up to 12 months in 1050 cancer patients with VTE. The primary efficacy event (a composite of recurrent thrombosis and major bleeding) occurred in 67 patients (12.8%) who received edoxaban and in 71 patients (13.5%) who received dalteparin (hazard ratio for edoxaban of 0.97; 95% CI 0.70–1.36; <span class="elsevierStyleItalic">P</span>=.0056 for non-inferiority). <span class="elsevierStyleItalic">Caravaggio</span> (<a id="intr0010" class="elsevierStyleInterRef" href="https://clinicaltrials.gov/NCT03045406">NCT03045406</a>) is an open-label randomized clinical trial comparing apixaban vs dalteparin in the first 6 months of treatment of symptomatic or incidental VTE in cancer patients over the age of 18 years. The <span class="elsevierStyleItalic">Select-D</span> study (ISRCTN86712308) is an open-label randomized clinical trial which compares dalteparin vs rivaroxaban in patients with VTE and cancer. Moreover, patients with residual deep venous thrombosis in the sixth month of treatment will be randomized to rivaroxaban or placebo for an additional 6 months. <span class="elsevierStyleItalic">CANVAS</span> (<a id="intr0015" class="elsevierStyleInterRef" href="https://clinicaltrials.gov/NCT02744092">NCT02744092</a>) is an open-label randomized clinical trial that will compare the efficacy and safety of 6 months’ treatment with direct-acting oral anticoagulants vs warfarin in cancer patients with confirmed VTE.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Between 8% and 12% of patients with VTE (presumably idiopathic) are diagnosed with occult cancer in the early follow-up period. In view of the results of several studies that have evaluated the usefulness of exhaustive cancer screening in this group of patients,<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">9</span></a> the International Society of Thrombosis and Hemostasis recommends limited screening, including clinical history, physical examination, basic clinical laboratory tests (complete blood count, coagulation, liver function tests), and chest X-ray.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">10</span></a> Recently, a risk prediction score has been developed for occult cancer in patients with VTE. This scale comprises the following variables: male (1 point), >70 years (2 points), chronic lung disease (1 point), anemia (2 points), platelets ≥350×10<span class="elsevierStyleSup">9</span>/L (1 point), previous surgery (minus 2 points), VTE (minus 1 point).<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">11</span></a> In an external, retrospective validation of this scale, occult cancer was identified in 13.8% of high-risk patients (i.e., score≥3) compared to 3.6% of low-risk patients.</p><p id="par0030" class="elsevierStylePara elsevierViewall">In conclusion, the treatment of VTE associated with malignant disease is a challenge in daily clinical practice. Well-designed studies are needed to identify patients receiving chemotherapy in an outpatient setting in whom pharmacological thromboprophylaxis has an acceptable risk-benefit balance. In addition, ongoing clinical trials are needed to establish the role of direct-acting anticoagulants in the initial and long-term treatment of VTE associated with cancer.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflict of Interests</span><p id="par0035" class="elsevierStylePara elsevierViewall">DJ is a member of the Data and Safety Monitoring Board of the Caravaggio clinical trial.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflict of Interests" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Barrios D, Jara-Palomares L, Jiménez D. Enfermedad tromboembólica venosa y cáncer: un reto para los clínicos. Arch Bronconeumol. 2018;54:359–360.</p>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Hb: hemoglobin; BMI: body mass index.</p><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Score: 0 points, low risk; 1–2 points, intermediate risk; ≥3 points, high risk.</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Source</span>: Khorana et al.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">4</span></a></p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Patient Characteristics \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Score \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Cancer site</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Very high risk (pancreas, stomach) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>High risk (lung, lymphoma, gynecological, bladder, testicular) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Platelet count ≥350×10</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">9</span></span><span class="elsevierStyleItalic">/L (before chemotherapy)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Hb<10</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">g/L or use of erythropoiesis-stimulating agents</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Leukocyte count>11,000/mm</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">3</span></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">BMI≥35</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">kg/m</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">2</span></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1784130.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Khorana Risk Model.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:11 [ 0 => array:3 [ "identificador" => "bib0060" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.A. Heit" 1 => "W.M. O’Fallon" 2 => "T.M. Petterson" 3 => "C.M. Lohse" 4 => "M.D. Silverstein" 5 => "D.N. Mohr" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Intern Med" "fecha" => "2002" "volumen" => "162" "paginaInicial" => "1245" "paginaFinal" => "1248" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12038942" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0065" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer-associated thrombosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "G.C. Connolly" 1 => "C.W. Francis" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Hematol Am Soc Hematol Educ Prog" "fecha" => "2013" "volumen" => "2013" "paginaInicial" => "684" "paginaFinal" => "691" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0070" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A.A. Khorana" 1 => "C.W. Francis" 2 => "E. Culakova" 3 => "N.M. Kuderer" 4 => "G.H. Lyman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1538-7836.2007.02374.x" "Revista" => array:6 [ "tituloSerie" => "J Thromb Haemost" "fecha" => "2007" "volumen" => "5" "paginaInicial" => "632" "paginaFinal" => "634" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17319909" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0075" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Development and validation of a predictive model for chemotherapy-associated thrombosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A.A. Khorana" 1 => "N.M. Kuderer" 2 => "E. Culakova" 3 => "G.H. Lyman" 4 => "C.W. Francis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2007-10-116327" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2008" "volumen" => "111" "paginaInicial" => "4902" "paginaFinal" => "4907" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18216292" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0080" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Carrier" 1 => "G. Le Gal" 2 => "J. Tay" 3 => "C. Wu" 4 => "A.Y. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1538-7836.2011.04215.x" "Revista" => array:6 [ "tituloSerie" => "J Thromb Haemost" "fecha" => "2011" "volumen" => "9" "paginaInicial" => "653" "paginaFinal" => "663" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21255254" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0085" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antithrombotic therapy for VTE disease: chest guideline and expert panel report" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Kearon" 1 => "E.A. Akl" 2 => "J. Ornelas" 3 => "A. Blaivas" 4 => "D. Jimenez" 5 => "H. Bounameaux" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.chest.2015.11.026" "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "2016" "volumen" => "149" "paginaInicial" => "315" "paginaFinal" => "352" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26867832" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0090" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vitamin K antagonists after 6 months of low-molecular-weight heparin in cancer patients with venous thromboembolism" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Chai-Adisaksopha" 1 => "A. Iorio" 2 => "M.A. Crowther" 3 => "J. de Miguel" 4 => "E. Salgado" 5 => "M. Zdraveska" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.amjmed.2017.11.042" "Revista" => array:6 [ "tituloSerie" => "Am J Med" "fecha" => "2018" "volumen" => "131" "paginaInicial" => "430" "paginaFinal" => "437" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29274307" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0095" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Edoxaban for the treatment of cancer-associated venous thromboembolism" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.E. Raskob" 1 => "N. van Es" 2 => "P. Verhamme" 3 => "M. Carrier" 4 => "M. di Nisio" 5 => "D. Garcia" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1711948" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2018" "volumen" => "378" "paginaInicial" => "615" "paginaFinal" => "624" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29231094" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0100" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Screening for occult cancer in unprovoked venous thromboembolism" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Carrier" 1 => "A. Lazo-Langner" 2 => "S. Shivakumar" 3 => "V. Tagalakis" 4 => "R. Zarychanski" 5 => "S. Solymoss" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1506623" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2015" "volumen" => "373" "paginaInicial" => "697" "paginaFinal" => "704" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26095467" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0105" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Delluc" 1 => "D. Antic" 2 => "R. Lecumberri" 3 => "C. Ay" 4 => "G. Meyer" 5 => "M. Carrier" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jth.13791" "Revista" => array:7 [ "tituloSerie" => "J Thromb Haemost" "fecha" => "2017" "volumen" => "15" "paginaInicial" => "2076" "paginaFinal" => "2079" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28851126" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1933287414002682" "estado" => "S300" "issn" => "19332874" ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0110" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Development of a risk prediction score for occult cancer in patients with VTE" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Jara-Palomares" 1 => "R. Otero" 2 => "D. Jimenez" 3 => "M. Carrier" 4 => "I. Tzoran" 5 => "B. Brenner" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.chest.2016.10.025" "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "2017" "volumen" => "151" "paginaInicial" => "564" "paginaFinal" => "571" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27815153" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15792129/0000005400000007/v1_201807020412/S1579212918301575/v1_201807020412/en/main.assets" "Apartado" => array:4 [ "identificador" => "45360" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorials" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15792129/0000005400000007/v1_201807020412/S1579212918301575/v1_201807020412/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212918301575?idApp=UINPBA00003Z" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 11 | 2 | 13 |
| 2024 October | 39 | 18 | 57 |
| 2024 September | 44 | 20 | 64 |
| 2024 August | 59 | 42 | 101 |
| 2024 July | 61 | 22 | 83 |
| 2024 June | 70 | 21 | 91 |
| 2024 May | 92 | 29 | 121 |
| 2024 April | 40 | 27 | 67 |
| 2024 March | 49 | 22 | 71 |
| 2024 February | 31 | 16 | 47 |
| 2023 August | 3 | 0 | 3 |
| 2023 May | 1 | 0 | 1 |
| 2023 March | 13 | 3 | 16 |
| 2023 February | 54 | 16 | 70 |
| 2023 January | 35 | 29 | 64 |
| 2022 December | 68 | 33 | 101 |
| 2022 November | 67 | 25 | 92 |
| 2022 October | 62 | 44 | 106 |
| 2022 September | 31 | 23 | 54 |
| 2022 August | 40 | 44 | 84 |
| 2022 July | 32 | 44 | 76 |
| 2022 June | 30 | 35 | 65 |
| 2022 May | 31 | 56 | 87 |
| 2022 April | 35 | 30 | 65 |
| 2022 March | 33 | 43 | 76 |
| 2022 February | 43 | 21 | 64 |
| 2022 January | 56 | 47 | 103 |
| 2021 December | 64 | 45 | 109 |
| 2021 November | 73 | 42 | 115 |
| 2021 October | 51 | 64 | 115 |
| 2021 September | 40 | 60 | 100 |
| 2021 August | 25 | 32 | 57 |
| 2021 July | 42 | 32 | 74 |
| 2021 June | 39 | 31 | 70 |
| 2021 May | 45 | 48 | 93 |
| 2021 April | 87 | 131 | 218 |
| 2021 March | 46 | 22 | 68 |
| 2021 February | 30 | 30 | 60 |
| 2021 January | 33 | 8 | 41 |
| 2020 December | 40 | 25 | 65 |
| 2020 November | 34 | 24 | 58 |
| 2020 October | 28 | 32 | 60 |
| 2020 September | 41 | 14 | 55 |
| 2020 August | 21 | 20 | 41 |
| 2020 July | 34 | 22 | 56 |
| 2020 June | 1 | 0 | 1 |
| 2020 March | 38 | 9 | 47 |
| 2020 February | 38 | 14 | 52 |
| 2020 January | 48 | 24 | 72 |
| 2019 December | 32 | 16 | 48 |
| 2019 November | 23 | 11 | 34 |
| 2019 October | 510 | 17 | 527 |
| 2019 September | 34 | 14 | 48 |
| 2019 August | 32 | 19 | 51 |
| 2019 July | 29 | 29 | 58 |
| 2019 June | 37 | 16 | 53 |
| 2019 May | 46 | 26 | 72 |
| 2019 April | 42 | 22 | 64 |
| 2019 March | 39 | 19 | 58 |
| 2019 February | 45 | 27 | 72 |
| 2019 January | 26 | 16 | 42 |
| 2018 December | 1 | 0 | 1 |
Show all
